logo

Alnylam Pharmaceuticals Inc. (ALNY)



Trade ALNY now with
  Date
  Headline
5/18/2022 8:04:41 AM Alnylam : Canada Authorizes OXLUMO For Treatment Of Primary Hyperoxaluria Type 1 To Lower Urinary Oxalate Levels
4/28/2022 8:05:22 AM Alnylam Pharmaceuticals Q1 Net Loss Widens To $240.3 Mln From $200.3 Mln Last Year
4/5/2022 4:07:55 PM Alnylam Announces Retirement Of Steven Paul From Board Of Directors
4/4/2022 7:37:42 AM Alnylam : FDA Extends Review Timeline Of NDA For Vutrisiran To July 14, 2022; No Additional Clinical Data Requested
3/17/2022 7:38:19 AM Alnylam Pharma Says Filed Patent Infringement Suits Against Pfizer And Moderna On MRNA COVID-19 Vaccines
3/16/2022 7:33:39 AM Alnylam Issues 2021 Corporate Responsibility Report
3/1/2022 7:12:24 AM Alnylam Pharma Says FDA Accepts SNDA For OXLUMO For Advanced Primary Hyperoxaluria Type 1
2/10/2022 8:09:06 AM Alnylam Pharma Q4 GAAP Loss Per Share $2.16; Non-GAAP Loss Per Share $1.69